Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study.
Jun-Hyung ChoPublished in: Expert review of anti-infective therapy (2024)
www.clinicaltrials.gov identifier is NCT05453994.